China approves AstraZeneca's Orpathys for gastric cancer

AstraZeneca's selective MET inhibitor Orpathys has won conditional approval in China for a new indication in MET-amplified gastric cancer, marking the first targeted therapy approved in the country for the biomarker-defined subgroup and underscoring China's growing role in precision oncology drug development.

Raccontata daglobal.chinadaily.com.cn